Skip to main content
. 2019 Aug 7;146(7):1917–1929. doi: 10.1002/ijc.32583

Figure 2.

Figure 2

The comparison of progression‐free survival in the first‐line of treatment (PFS1) between patients that received a pertuzumab‐based regimen (Pert) and those who did not (No Pert) in the overall population (a), in triple‐positive patients (b), in Er‐ or PgR‐positive patients (c) and in HRs‐negative patients (d). Abbreviations: Er, estrogen receptor; PgR, progesterone receptor; HRs, hormone receptors.